Results of an animal study are published in the March 1, 2006 issue of Cancer Research, and the researchers are now applying to regulatory agencies to translate their work into human clinical trials.
Gliomas are highly invasive tumors with poorly defined borders that intermingle with healthy brain tissue, making complete surgical removal nearly impossible. Furthermore, cells separate from the main tumor and migrate to form satellites that escape treatment and often lead to recurrence.
Researchers at the Maxine Dunitz Neurosurgical Institute documented several years ago that some neural stem cells "immature" cells that can differentiate into central nervous system cells have the ability to target and track glioma cells in the brain, even as they migrate. The researchers identified the mechanism that enables certain neural stem cells to develop this tracking ability and genetically engineered neural stem cells to transport several cytokines proteins that regulate immune responses to track down and destroy glioma cells.
In 2002, the scientists reported that they had produced central nervous system cells from stem cells derived from bone marrow. Because these stem cells originate in the bone marrow instead of the brain or fetal or embryonic tissue, there is an unlimited supply of cells that are free of ethical and tissue-rejection issues.
This study provides the first documentation that the marrow-derived stem cells possess the same tumor-tracking capability of other neural stem cells. It also includes the first report on the use of the cytokine interleukin-23 (IL-23) as a po
Contact: Sandy Van
Cedars-Sinai Medical Center